Budesonide-MMX® Clinical Studies
UC clinical trial
Please click here to see if you may be eligible for the study
EU Protocol study CB-01-02/02
Randomized Placebo Controlled Trial of Budesonide-MMX® (CB-01-02) 6mg and 9mg in patients with Ulcerative Colitis. The study will compare budesonide-MMX® 6 mg and budesonide-MMX® 9 mg tablets to placebo and to Entocort® 3 x 3 mg capsules in four parallel groups of patients over an 8 week treatment period.
Back to top
US Protocol study
CB-01-02/01
Randomized Placebo Controlled Trial of Budesonide-MMX® (CB-01-02) 6mg and 9mg in patients with Ulcerative Colitis. The study will compare budesonide-MMX® 6 mg and budesonide-MMX® 9 mg tablets to placebo and to Asacol® 6 x 400 mg tablets, in four parallel groups of patients over an 8-week treatment period.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00679432
Contact:
Randomized Placebo Controlled Trial of Budesonide-MMX® (CB-01-02) 6mg and 9mg in patients with Ulcerative Colitis. The study will compare budesonide-MMX® 6 mg and budesonide-MMX® 9 mg tablets to placebo and to Asacol® 6 x 400 mg tablets, in four parallel groups of patients over an 8-week treatment period.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00679432
Contact:
Kees Boot, Project Director,
Clinical Operations
ICON Clinical Research
Tel: +1 (858) 795-8303 Email:
Kees.Boot@iconplc.com
Please click here to see if you may be eligible for the study
EU Protocol study CB-01-02/02
Randomized Placebo Controlled Trial of Budesonide-MMX® (CB-01-02) 6mg and 9mg in patients with Ulcerative Colitis. The study will compare budesonide-MMX® 6 mg and budesonide-MMX® 9 mg tablets to placebo and to Entocort® 3 x 3 mg capsules in four parallel groups of patients over an 8 week treatment period.
Enrollment
Completed
Contacts and
Locations
Please refer to this study as CB-01-02/02
Please refer to this study as CB-01-02/02
| Protocol number | Inclusion / Exclusion
Criteria |
Study Phase | Language |
|---|---|---|---|
| CB-01-02/01 | US study (pdf) | Phase III | EN |
|
This page includes links to documents in Portable Document File (PDF) format. To read PDF documents you may need to download the free Adobe Acrobat Reader. For PDF accessibility help, visit Access Adobe. These links will open in a new browser window. |
Back to top